Helicobacter pylori eradication – insights from novel recommendations of Polish Society of Gastroenterology Review article
Article Sidebar
Published:
Dec 31, 2023
Keywords:
Helicobacter pylori, H. pylori, eradication, gastritis, gastric cancer, atrophy, quadruple therapy
Main Article Content
Abstract
Helicobacter pylori infection remains a major health problem worldwide, due to considerable morbidity and mortality caused by peptic ulcer disease and gastric malignancies. In 2023 Governing Board of the Polish Society of Gastroenterology revealed novel report “Diagnostic and therapeutic recommendations on Helicobacter pylori infection” which constitute an update of the previous recommendations issued in 2014.
The recommendations focuses on practical issues of H. pylori infection, in particular determine which patients need to be tested, treated for infection and discussed recommended treatment algorithms.
Article Details
How to Cite
Przybylska-Feluś, M., & Zwolińska-Wcisło, M. (2023). Helicobacter pylori eradication – insights from novel recommendations of Polish Society of Gastroenterology. Medycyna Faktow (J EBM), 16(4(61), 290-294. https://doi.org/10.24292/01.MF.0423.01
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Malfertheiner P, Megraud F, Rokkas T et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022; 71: 1724-62.
2. Jaroń K, Pietrzak A, Daniluk J et al. Diagnostic and therapeutic recommendations on Helicobacter pylori infection. Recommendations of the working group of the Polish Society of Gastroenterology. Gastroenterology Rev. 2023; 18(3): 225-48.
3. Kotilea K, Bontems P, Touati E. Epidemiology, Diagnosis and Risk Factors of Helicobacter pylori Infection. Adv Exp Med Biol. 2019; 1149: 17-33.
4. Hanafiah A, Lopes BS. Genetic diversity and virulence characteristics of Helicobacter pylori isolates in different human ethnic groups. Infect Genet Evol. 2020; 78: 104135.
5. Jones NL, Koletzko S, Goodman K et al. ESPGHAN, NASPGHAN. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017; 64(6): 991-1003.
6. Muhammad JM, Sugiyama T, Zaidi SF. Gastric pathophysiological ins and outs of helicobacter pylori: a review. J Pak Med Assoc. 2013; 63(12): 1528–33.
7. Sugimoto M, Yamaoka Y, Shirai N et al. Role of renin-angiotensin system in gastric oncogenesis. J Gastroenterol Hepatol. 2012; 27(3): 442-51.
8. Chojnacki C, Konrad P, Błońska A et al. Usefulness of the hydrogen breath test in patients with functional dyspepsia. Prz Gastroenterol. 2020; 15(4): 338-42.
9. Konrad P, Chojnacki J, Gąsiorowska A et al. Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection. Prz Gastroenterol. 2018; 13(3): 213-17.
10. Dharan M, Wozny D Helicobacter pylori infection and small intestinal bacterial overgrowth-more than what meets the eye. World J Clin Cases. 2022; 10(21): 7209-14.
11. Balamtekin N, Cumhur Artuk C et al. The effect of Helicobacter pylori on the presentation and clinical course of coronavirus disease 2019 infection. J Pediatr Gastroenterol Nutr. 2021; 72(4): 511-13.
12. World Gastroenterology Organisation: Global guidelines Helicobacter pylori. 2021.
13. Ding S-Z, Du Y-Q, Lui H et al. Chinese consensus report on family-based helicobacter pylori infection control and management (2021 edition). Gut. 2022; 71(2): 238-53.
14. Ferenc S, Gnus J, Kościelna M et al. High antibiotic resistance of Helicobacter pylori and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland. Helicobacter. 2017; 22(2): e12365.
15. Nyssen OP, Perez‐Aisa A, Castro‐Fernandez M et al. European Registry on Helicobacter pylori management: Single‐capsule bismuth quadruple therapy is effective in real‐world clinical practice. United European Gastroenterol J. 2021; 9(1): 38-46.
16. Lee M, Kemp JA, Canning A et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med.1999; 159(19): 2312-6.
17. Dąbrowski A, Hartleb M, Nowakowska-Duława E et al. (ed). Choroby układu pokarmowego. In: Interna Szczeklika – Podręcznik chorób wewnętrznych. Medycyna Praktyczna, Kraków 2022.
2. Jaroń K, Pietrzak A, Daniluk J et al. Diagnostic and therapeutic recommendations on Helicobacter pylori infection. Recommendations of the working group of the Polish Society of Gastroenterology. Gastroenterology Rev. 2023; 18(3): 225-48.
3. Kotilea K, Bontems P, Touati E. Epidemiology, Diagnosis and Risk Factors of Helicobacter pylori Infection. Adv Exp Med Biol. 2019; 1149: 17-33.
4. Hanafiah A, Lopes BS. Genetic diversity and virulence characteristics of Helicobacter pylori isolates in different human ethnic groups. Infect Genet Evol. 2020; 78: 104135.
5. Jones NL, Koletzko S, Goodman K et al. ESPGHAN, NASPGHAN. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017; 64(6): 991-1003.
6. Muhammad JM, Sugiyama T, Zaidi SF. Gastric pathophysiological ins and outs of helicobacter pylori: a review. J Pak Med Assoc. 2013; 63(12): 1528–33.
7. Sugimoto M, Yamaoka Y, Shirai N et al. Role of renin-angiotensin system in gastric oncogenesis. J Gastroenterol Hepatol. 2012; 27(3): 442-51.
8. Chojnacki C, Konrad P, Błońska A et al. Usefulness of the hydrogen breath test in patients with functional dyspepsia. Prz Gastroenterol. 2020; 15(4): 338-42.
9. Konrad P, Chojnacki J, Gąsiorowska A et al. Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection. Prz Gastroenterol. 2018; 13(3): 213-17.
10. Dharan M, Wozny D Helicobacter pylori infection and small intestinal bacterial overgrowth-more than what meets the eye. World J Clin Cases. 2022; 10(21): 7209-14.
11. Balamtekin N, Cumhur Artuk C et al. The effect of Helicobacter pylori on the presentation and clinical course of coronavirus disease 2019 infection. J Pediatr Gastroenterol Nutr. 2021; 72(4): 511-13.
12. World Gastroenterology Organisation: Global guidelines Helicobacter pylori. 2021.
13. Ding S-Z, Du Y-Q, Lui H et al. Chinese consensus report on family-based helicobacter pylori infection control and management (2021 edition). Gut. 2022; 71(2): 238-53.
14. Ferenc S, Gnus J, Kościelna M et al. High antibiotic resistance of Helicobacter pylori and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland. Helicobacter. 2017; 22(2): e12365.
15. Nyssen OP, Perez‐Aisa A, Castro‐Fernandez M et al. European Registry on Helicobacter pylori management: Single‐capsule bismuth quadruple therapy is effective in real‐world clinical practice. United European Gastroenterol J. 2021; 9(1): 38-46.
16. Lee M, Kemp JA, Canning A et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med.1999; 159(19): 2312-6.
17. Dąbrowski A, Hartleb M, Nowakowska-Duława E et al. (ed). Choroby układu pokarmowego. In: Interna Szczeklika – Podręcznik chorób wewnętrznych. Medycyna Praktyczna, Kraków 2022.